Attention Deficit Hyperactivity Disorder (ADHD): Disease Insights & Market Forecasts to 2024 - ResearchAndMarkets.com

DUBLIN--()--The "Attention Deficit Hyperactivity Disorder (ADHD): Disease Insights and Market Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering.

Disease Indication Overview:

This section highlights the basic definition, causes and symptoms of disease and details the types of Attention Deficit Hyperactivity Disorder (ADHD) disease. Further details on the profile of Attention Deficit Hyperactivity Disorder (ADHD) patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report.

Epidemiology Forecasts to 2024:

This section of the report provides the overview of Attention Deficit Hyperactivity Disorder (ADHD) diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015-2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Drugs Overview and Attribute Analysis:

This part of the report highlights the importance of factors influencing the physician prescription decisions in Attention Deficit Hyperactivity Disorder (ADHD) disease including efficacy factors, Tolerability factors, Monitoring requirements and pricing factors. The report further details the drugs prescribed or expected to be prescribed in Attention Deficit Hyperactivity Disorder (ADHD) disease by the physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drugs in the Attention Deficit Hyperactivity Disorder (ADHD) market.

Drugs and Market Forecast to 2024:

The forecasts are developed based on the detailed drug attribute analysis, conducted by Pharmascroll, as shared in the previous section. It is important to note that the Forecasts conducted by Pharmascroll are not based on simple projections, and are developed meticulously based on a complex forecasting model, owned by Pharmascroll, using multiple assumptions related to launch dates of the products in the market, price of the products, adherence and compliance rates of the products, dosages of the products etc.

Companies Mentioned

  • Shionogi
  • Shire
  • Supernus Pharmaceuticals
  • Yale University
  • Chugai Pharmaceutical
  • Eli Lilly
  • GlaxoSmithKline
  • New River Pharmaceuticals
  • Johnson & Johnson
  • Celgene
  • Elan
  • Novartis
  • Teva Pharmaceutical Industries
  • Cephalon
  • Alkermes
  • Recro Pharma
  • Neos Therapeutics
  • Afecta Pharmaceuticals
  • Sumitomo Dainippon Pharma
  • Sepracor
  • Aquestive Therapeutics
  • KemPharm

Key Topics Covered:

1 Table of Contents

2 Executive Summary

3 Disease Overview

4 Disease Epidemiology

5 Physician's Insights

6 Competitive Assessment and Attribute Analysis - Key Therapies

7 Pipeline Assessment

8 Market Outlook

9 Sales and Patient Forecast for Key Drugs

10 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/bqgm8m/attention_deficit?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs, Mental Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs, Mental Disorders Drugs